Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783914 | 1.00 | FFAR1 (0.36) | FFAR1GAASMN1; SMN2PPARGKLKB1 | |
| SCHEMBL21783861 | 0.91 | FFAR1 (0.35) | FFAR1GAASMN1; SMN2PPARGKLKB1 | |
| SCHEMBL21783868 | 0.85 | FFAR1 (0.39) | FFAR1GAASMN1; SMN2PDE4APDE4B | |
| SCHEMBL21773641 | 0.84 | IDO1 (0.44) | FFAR1SMN1; SMN2FNTAFNTBMAPT | |
| SCHEMBL21773740 | 0.84 | IDO1 (0.44) | FFAR1SMN1; SMN2FNTAFNTBMAPT | |
| SCHEMBL21773643 | 0.84 | IDO1 (0.44) | FFAR1SMN1; SMN2FNTAFNTBMAPT | |
| SCHEMBL21773835 | 0.84 | IDO1 (0.44) | FFAR1SMN1; SMN2FNTAFNTBMAPT | |
| SCHEMBL21773700 | 0.84 | IDO1 (0.44) | FFAR1SMN1; SMN2FNTAFNTBMAPT | |
| SCHEMBL21783913 | 0.84 | GAA (0.39) | FFAR1GAAPPARG | |
| SCHEMBL21783849 | 0.84 | GAA (0.39) | FFAR1GAAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253525-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | FFAR1 3772/4885GAA 316/4885SMN1; SMN2 3908/4885 |
| US-20200069695-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | FFAR1 3772/4885GAA 316/4885SMN1; SMN2 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.